D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 136 SEK 1.12% Market Closed
Market Cap: 2.2B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Devyser Diagnostics AB
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Free Cash Flow
-kr101.7m
CAGR 3-Years
-232%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Free Cash Flow
kr377.4m
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Free Cash Flow
-kr3m
CAGR 3-Years
68%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Free Cash Flow
kr655m
CAGR 3-Years
8%
CAGR 5-Years
14%
CAGR 10-Years
16%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Free Cash Flow
kr3.3B
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
38%
BioArctic AB
STO:BIOA B
Free Cash Flow
kr302.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.2B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
123.02 SEK
Overvaluation 10%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Free Cash Flow?
Free Cash Flow
-101.7m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Free Cash Flow amounts to -101.7m SEK.

What is Devyser Diagnostics AB's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-232%

Over the last year, the Free Cash Flow growth was -53%. The average annual Free Cash Flow growth rates for Devyser Diagnostics AB have been -232% over the past three years .

Back to Top